Effect of a rehabilitation program on magnesium levels in women with vulvovaginal atrophy in surgical menopause
https://doi.org/10.17749/2949-5873/rehabil.2024.25
Abstract
Background. Magnesium deficiency (MD) is a prevalent issue among women after radical treatment for gynecological cancers, particularly in the context of surgical menopause. A lack of magnesium can significantly affect the quality of life of patients, causing various somatic and psychological disorders.
Objective: To assess the impact of a comprehensive “active” rehabilitation program on magnesium levels in women with vulvovaginal atrophy (VVA) in surgical menopause.
Material and methods. The study included 140 women with VVA after radical treatment for female genital cancer. Participants were divided into two groups: Group 1 (n=70) received comprehensive “active” rehabilitation, while Group 2 (n=70) underwent standard rehabilitation. MD manifestations were evaluated at Months 1, 3, 6, and 12 after surgery using the Magnesium Deficiency Questionnaire (MDQ) and the Magnesium Deficiency Assessment Test (MDAT). Additionally, laboratory tests were performed to measure blood magnesium levels.
Results. In the group receiving comprehensive “active” rehabilitation, a significant reduction in MD was observed as early as Month 1 (37.84±14.89 MDQ points compared to 65.10±26.30 points in the control group, p <0.01). By Month 3, symptoms of MD were nearly completely resolved (22.34±9.17 MDQ points). A similar trend was noted in MDAT results. Blood magnesium levels in Group 1 increased from 0.7±0.01 to 0.81±0.08 mmol/l at Month 1 and reached 0.90±0.06 mmol/l at Month 12. In contrast, the magnesium levels in Group 2 remained stable at 0.71–0.73 mmol/l throughout the study period.
Conclusion. The comprehensive “active” rehabilitation program demonstrated high efficacy in correcting MD in women with VVA undergoing surgical menopause, contributing to an improvement in their quality of life.
About the Authors
A. V. Vorobev
Sechenov University
Russian Federation
Russian Federation
Alexander V. Vorobev, PhD, Assoc. Prof.
WoS ResearcherID: F-8804-2017
Scopus Author ID: 57191966265
8/2 Trubetskaya Str., Moscow 119048
A. B. Hajiyeva
Baku branch of Sechenov University
Azerbaijan
Azerbaijan
Aygun B. Hajiyeva
139 Huseyn Cavid Ave, Baku AZ1143
E. A. Son
Sechenov University
Russian Federation
Russian Federation
Elena А. Son, PhD
Scopus Author ID: 19837664400
8/2 Trubetskaya Str., Moscow 119048
References
1. Wolf F.I., Cittadini A.R., Maier J.A. Magnesium and tumors: ally or foe? Cancer Treat Rev. 2009; 35 (4): 378–82. https://doi.org/10.1016/j.ctrv.2009.01.003.
2. Castiglioni S., Maier J.A. Magnesium and cancer: a dangerous liason. Magnes Res. 2011; 24 (3): S92–100. https://doi.org/0.1684/mrh.2011.0285.
3. Blaszczyk U., Duda-Chodak A. Magnesium: its role in nutrition and carcinogenesis. Rocz Panstw Zakl Hig. 2013; 64 (3): 165–71.
4. Ashique S., Kumar S., Hussain A., et al. A narrative review on the role of magnesium in immune regulation, inflammation, infectious diseases, and cancer. J Health Popul Nutr. 2023; 42 (1): 74. https://doi.org/10.1186/s41043-023-00423-0.
5. Gile J., Ruan G., Abeykoon J., et al. Magnesium: the overlooked electrolyte in blood cancers? Blood Rev. 2020; 44: 100676. https://doi.org/10.1016/j.blre.2020.100676.
6. Blinov D.V., Solopova A.G., Malykh-Bakhtina М.P., et al. The role
7. of magnesium deficiency control in recovery after treatment for oncogynecological diseases. Reabilitologia / Journal of Medical Rehabilitation. 2024; 2 (2): 186–96 (in Russ.). https://doi.org/10.17749/2949-5873/rehabil.2024.19.
8. Nasulewicz A., Wietrzyk J., Wolf F.I., et al. Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta. 2004; 1739 (1): 26–32. https://doi.org/10.1016/j.bbadis.2004.08.003.
9. Workeneh B.T., Uppal N.N., Jhaveri K.D., Rondon-Berrios H. Hypomagnesemia in the cancer patient. Kidney360. 2020; 2 (1): 154–66. https://doi.org/10.34067/KID.0005622020.
10. Blinov D.V., Solopova A.G., Achkasov E.E., et al. The role of magnesium deficiency correction in the rehabilitation of women with climacteric syndrome and surgical menopause: results of the MAGYN study. Obstetrics, Gynecology and Reproduction. 2022; 16 (6): 676–91 (in Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.371.
11. Trisvetova E.L. Magnesium in clinical practice. Rational Pharmacotherapy in Cardiology. 2012; 8 (4): 545–53 (in Russ.).
12. Slagle P. Magnificent magnesium. The Way Up Newsletter. Vol. 30; 08-15-01.
13. Tarasov E.A., Blinov D.V., Zimovina U.V., Sandakova E.A. Magnesium deficiency and stress: Issues of their relationship, diagnostic tests, and approaches to therapy. Therapeutic Archive. 2015; 87 (9): 114–22 (in Russ.). https://doi.org/10.17116/terarkh2015879114-122.
14. Blinov D.V., Ushakova T.I., Makatsariya N.A., et al. Hormonal contraception and magnesium deficiency: a subanalysis of the MAGYN study. Obstetrics, Gynecology and Reproduction. 2017; 11 (1): 36–48 (in Russ.). https://doi.org/10.17749/2313-7347.2017.11.1. 036-048.
15. Passarelli S., Free C.M., Shepon A., et al. Global estimation of dietary micronutrient inadequacies: a modelling analysis. Lancet Glob Health. 2024; 12 (10): e1590–9. https://doi.org/10.1016/S2214-109X(24)00276-6.
16. Babapour M., Mohammadi H., Kazemi M., et al. Associations between serum magnesium concentrations and polycystic ovary syndrome status: a systematic review and meta-analysis. Biol Trace Elem Res. 2021; 199 (4): 1297–305. https://doi.org/10.1007/s12011-020-02275-9.
Review
For citations:
Vorobev A.V., Hajiyeva A.B., Son E.A. Effect of a rehabilitation program on magnesium levels in women with vulvovaginal atrophy in surgical menopause. Journal of Medical Rehabilitation. 2024;2(4):336-343. (In Russ.) https://doi.org/10.17749/2949-5873/rehabil.2024.25
Views:
1043
Email this article 